Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - June 2013


Advanced Portfolio Management for the Pharma and Biotech Industries

10 Jun 2013 - 12 Jun 2013 - Zurich, Switzerland



Bookmark and Share


In an era of declining R&D productivity and unprecedented loss of blockbuster patent exclusivity, the need to maximize the value of its core assets under ever constrained budgetary and human resources has never been more critical to the Pharmaceutical and Biotechnology industry. An integral part of strategic and business planning, the portfolio management process influences decisions that directly impact company fortunes — especially when advancing the right compounds under risk and uncertainty to create the potential for billions of dollars in long-term revenue.

Effective portfolio management requires foresight, discipline, preparation, and diligence, a serious challenge given the daily pressures faced by all organizations. Top-performing companies review, refresh, and execute their portfolio strategies on a continual basis through the application of excellent process, methodology, analysis, and decision making. For many organizations, however, numerous obstacles make it difficult to adopt a sustainably successful approach to portfolio management.

This Masterclass is your roadmap to maximizing portfolio value in accordance with management’s strategic and financial goals. Designed to improve companies’ abilities to progress compounds from the pre-clinical stage to commercial brand management, it showcases benchmarks and best practices for teams managing investments across the entire value chain – pre-clinical and clinical projects as well as marketed brand products.

The Masterclass will introduce the CREOPM™ Methodology, a unique, holistic framework for Portfolio Management developed by the trainer – Dr. Richard Bayney – President of Project & Portfolio Value Creation. Dr. Bayney, a 23-year veteran of the Pharmaceutical and Biotechnology industry, was Head of Strategic Planning at Bayer and Head of Portfolio Management & Decision Analysis at Bristol-Myers Squibb and Johnson & Johnson. CREOPM™ is an overarching Portfolio Management framework comprised of the following steps:

  • Categorize
  • Risk Analysis
  • Evaluate
  • Optimize
  • Prioritize
  • Manage

 

Reinforce your portfolio management strategy and enable execution with the CREOPM™ framework

Follow a step-by-step guide to improve strategic planning, create the criteria necessary to advance some projects while discontinuing others, and make the best use of constrained budgetary and human resources by maximizing strategic and financial value. Understand team members’ roles in portfolio analysis and how to influence executive decision-making irrespective of your hierarchical level within the organization.

Create nimble development strategies, boost revenues, and extend market exclusivity

Portfolio management of branded medicines stretches from discovery to patent expiration, so it is important to ensure that the transitions from drug discovery to clinical development, registration, and lifecycle management are relatively seamless through a carefully orchestrated ‘push-pull’ mechanism i.e. ‘push’ from discovery and ‘pull’ from commercial. Learn how to create investment options, enable efficient decision-making, analyze ROI, and continuously build equity by maximizing portfolio value under constrained budgetary and human resources.

Build portfolio management excellence

In a rapidly evolving and increasingly competitive business environment, every company must strive to make the best use of its constrained resources by furthering those assets which, despite their inherent risks and uncertainties, are likely to provide sustainable growth. Irrespective of whether a formal group oversees the portfolio management process, executives expect that the best data and information will be presented to them in order for logically consistent and defensible decisions to be made. Explore the different capabilities required to build portfolio management excellence, examine how budgets and human resources can best be utilized, and track the enhanced value of better decisionmaking processes. Finally, create an organizational culture in which every stakeholder sees himself/herself as a contributor to successful enterprise portfolio management.

The Masterclass begins with well-founded theory and quickly moves to practical implementation and executive decision-making based on the trainer’s expertise and experience with 3 major Pharmaceutical and Biotechnology companies (1996-2007) as well as consulting across several industry verticals (2008-present).

Dr. Bayney’s emphasis is on helping organizations move from portfolio value creation to portfolio value maximization by putting in place sequential building blocks to attain protracted excellence in portfolio management.



Further information
Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!